VANCOUVER, BRITISH COLUMBIA--(Marketwire - Oct. 2, 2007) - WEX Pharmaceuticals Inc. (“WEX” or the “Company”) (TSX:WXI) is pleased to announce that the post hoc analysis of its WEX-014 trial, “Tetrodotoxin for Moderate to Severe Cancer Pain: A Randomized, Double Blind, Parallel Design Multicenter Study” is in press in the peer reviewed Journal of Pain and Symptom Management.
